View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 7, 2022

Calithera enrols first subject in Phase II NSCLC treatment trial

The multicentre, open-label trial will analyse sapanisertib monotherapy in NRF2-mutated sqNSCLC patients.

Calithera Biosciences has enroled the first subject in a Phase II clinical trial of sapanisertib (CB-228) in relapsed/refractory NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (sqNSCLC) patients.

NRF2 mutations are seen in a substantial sub-population of patients across various kinds of solid tumours. 

A potent and selective, dual mTORC 1/2 inhibitor, sapanisertib acts on a crucial survival mechanism in tumours that harbour these mutations. 

The company acquired sapanisertib from Takeda in the fourth quarter of last year.

Earlier, this compound showed single-agent clinical activity in relapsed/refractory NRF2-mutated sqNSCLC patients. 

The multicentre, open-label trial will analyse sapanisertib monotherapy in NRF2-mutated sqNSCLC patients.

These subjects must have advanced on or following platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti-PD-L1) irrespective of anti-CTLA-4.

In the trial, 2mg twice daily or 3mg once daily dose of sapanisertib will be administered in patients with sqNSCLC harbouring either wild-type (WT) or mutated NRF2.

The trial intends to validate sapanisertib’s selective activity in NRF2-mutated tumours versus WT tumours and refine the treatment dose in this biomarker-defined population.

Investigator-evaluated overall response rate (ORR) as per RECIST v1.1 and safety are the trial’s primary endpoints.

Duration of response, progression-free survival and overall survival are included as the secondary endpoints of the trial.

The trial findings would aid the company in commencing a registrational study in biomarker-specific sqNSCLC populations.

Calithera Biosciences president and CEO Susan Molineaux said: “Sapanisertib has the potential to be a first-in-class treatment for patients with NRF2-mutated squamous lung cancer, a patient population with poor prognosis and high unmet need. 

“This study is designed to further validate the NRF2 mutation as a selection biomarker, and we plan to share data from the trial by the first quarter of 2023.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena